Interventional Cardiology Devices – Market Insights – Europe

The European interventional cardiology device market is highly competitive and poised for growth, driven by increasing PCI volumes for complex CAD cases and the adoption of innovative devices and technologies. Favorable clinical evidence, particularly for coronary IVL, will continue to propel the market forward. Additionally, the adoption of novel products and diagnostic methods is expected to expand the eligible patient population and support continued market growth in the coming years.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC devices in Europe from 2019 through 2034.

There is a growing competition in the European IC device market.

What are the factors influencing complex PCI procedure volume growth in the European IC device market?

What are the future prospects of the companies operating in the market?

Which companies are expected to launch their products in the European IC device market?

Which new competitors are expected to enter this market?

The coronary stent segment is a highly competitive space, with the leading companies continuing to launch updates to their flagship devices.

What are the market share dynamics among the major competitors in the highly lucrative DES device market?

What competitive strategies are the companies implementing to gain market share in this market, and how are ASPs being impacted by the strong competition?

How is the market growing in the covered stent space?

What is the pipeline for next-generation BRS, and which companies are entering this highly competitive landscape?

The expansion of intravascular lithotripsy use is bolstering the IC device market.

How has the commercialization of coronary lithotripsy impacted the use of other products in the interventional cardiology space?

How does the future landscape look like in the lithotripsy space, and who are the expected new entrants?

New technologies are expected to receive approval in the near future and change the way complex PCIs are diagnosed and treated.

How CCTA adoption is expected to impact diagnostic angiography volumes in the coming years?

The adoption of premium-priced devices and new diagnostic methods will impact procedural success rates and overall PCI volumes in the European IC device market.

What is the impact of the latest generation of alternative coronary physiology modalities, such imaging-based FFR_angio and FFR_CT, on existing intravascular imaging technologies, including traditional FFR and IVUS?

How is the uptake of noninvasive imaging technologies in the European IC device market?

How will new clinical trial results impact IC device segments, procedures, competitors, and products?